Although anti-VEGF drugs are frequently used to treat ROP, they may have potential to exert long-term systemic adverse effects on other organs; thus, the recommended dosage for anti-VEGF agents is still under investigation [48,49,50]. This evidence concerns the gene VEGFA and retinopathy of prematurity.